{"id":"NCT04209400","sponsor":"VBI Vaccines Inc.","briefTitle":"Safety and Immunogenicity of Recombinant Hepatitis B Vaccine Sci-B-Vac® Compared to Engerix-B®","officialTitle":"A Comparative Randomized Double-Blind Study of Safety and Immunogenicity of Recombinant Hepatitis B Vaccine Sci-B-Vac® in Adult Study Subjects","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-04-18","primaryCompletion":"2015-04-20","completion":"2015-04-20","firstPosted":"2019-12-24","resultsPosted":"2022-07-25","lastUpdate":"2022-07-25"},"enrollment":100,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"PREVENTION"},"conditions":["Hepatitis B"],"interventions":[{"type":"BIOLOGICAL","name":"Sci-B-Vac®","otherNames":[]},{"type":"BIOLOGICAL","name":"Engerix-B®","otherNames":[]}],"arms":[{"label":"Sci-B-Vac®","type":"EXPERIMENTAL"},{"label":"Engerix-B®","type":"ACTIVE_COMPARATOR"}],"summary":"This study was a comparative, randomized, double-blind clinical study of the efficacy and safety of Sci-B-Vac® (10 μg dose) and the Engerix-B® (20 μg dose) vaccines in two parallel groups of hepatitis B-naive healthy adult subjects in Russia.","primaryOutcome":{"measure":"Seroconversion Rate","timeFrame":"Day 210","effectByArm":[{"arm":"Sci-B-Vac®","deltaMin":47,"sd":null},{"arm":"Engerix-B®","deltaMin":46,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"1"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["Russia"]},"refs":{"pmids":["33119068"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":50},"commonTop":["drowsiness","Hyperthermia","nausea","metallic taste","acute respiratory viral infection"]}}